Imatinib as a Potential Treatment for Sclerodermatous Chronic Graft-vs-Host Disease
نویسندگان
چکیده
منابع مشابه
Imatinib as a potential treatment for sclerodermatous chronic graft-vs-host disease.
Juan A. Moreno-Romero, MD; Francesc Fernández-Avilés, MD; Enric Carreras, MD; Montserrat Rovira, MD; Carmen Martı́nez, MD; José M. Mascaró Jr, MD; Department of Dermatology (Drs Moreno-Romero and Mascaró) and Bone Marrow Transplant Unit, Department of Hematology (Drs Fernández-Avilés, Carreras, Rovira, and Martı́nez), Hospital Clı́nic, University of Barcelona, and Department of Dermatology, Hospit...
متن کاملImatinib for sclerodermatous graft-versus-host disease in lung transplantation.
Imatinib has been proposed as a treatment for sclerodermatous chronic graft-versus-host disease (GVHD) due to its antifibrotic activity. Because imatinib has a potentially adverse effect on wound healing, the safety of its perioperative use in lung transplantation is unknown. Herein, we present a patient who underwent bilateral living-donor lobar lung transplantation for pulmonary complications ...
متن کاملLimited Impact of Imatinib in a Murine Model of Sclerodermatous Chronic Graft-versus-Host Disease
BACKGROUND Sclerodermatous chronic Graft-versus-Host Disease (scl-cGVHD) is one of the most severe form of cGVHD. The Platelet-derived Grotwth Factor (PDGF) and the Transforming Growth Factor-β (TGF-β) play a significant role in the fibrosing process occurring in scl-cGVHD. This prompted us to assess the impact of the PDGF-r and c-Abl tyrosine kinase inhibitor imatinib on scl-cGVHD. METHODS T...
متن کاملEtretinate therapy for refractory sclerodermatous chronic graft-versus-host disease.
Chronic graft-versus-host disease (GVHD) is the most common late complication of allogeneic bone marrow transplantation (BMT). The sclerodermatous form of the disease is often refractory to standard treatment modalities. Based on reports of response to etretinate, a synthetic retinoid, among patients with scleroderma, we have added etretinate to the treatment regimen of 32 patients with refract...
متن کاملImatinib and dasatinib as salvage therapy for sclerotic chronic graft-vs-host disease
AIM To assess the toxicity, tolerance, steroid-sparing capacity, effectiveness, and response rate to imatinib and dasatinib for the treatment of severe sclerotic chronic graft-vs-host disease (scGVHD). METHODS This retrospective study analyzed 8 consecutive patients with severe refractory scGVHD who received salvage therapy with imatinib. Patients intolerant and/or refractory to imatinib rece...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Archives of Dermatology
سال: 2008
ISSN: 0003-987X
DOI: 10.1001/archderm.144.9.1106